Diclofenac oral solution - Nautilus Neurosciences

Drug Profile

Diclofenac oral solution - Nautilus Neurosciences

Alternative Names: Cambia; Catafast; Potassium diclofenac for oral solution; PRO-513; Voltfast

Latest Information Update: 09 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Applied Pharma Research
  • Class Antirheumatics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Migraine

Most Recent Events

  • 06 Mar 2017 Diclofenac oral solution licensed to DKSH in the Philippines, Malaysia, Myanmar and Vietnam for the treatment of Migraine
  • 19 Jan 2017 Diclofenac oral solution licensed to Renhe Group in China, Taiwan, Hong Kong and Macao for the treatment of Migraine
  • 04 Jan 2016 Tribute has patent protection for Diclofenac oral solution in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top